Company profile for MAX BioPharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company will be a leader in a new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications. MAX BioPharma’s first ...
MAX BioPharma is a privately-held preclinical stage California-based biopharmaceutical company developing novel small molecule lipids as drug candidates for intervention in debilitating and fatal human diseases. The company will be a leader in a new field of Oxysterol Therapeutics® by leveraging a robust and growing intellectual property portfolio that will lead to treatments for numerous indications. MAX BioPharma’s first success based on small molecule lipids has contributed to the discovery of novel osteogenic oxysterol compounds that

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2870 Colorado Ave, Santa Monica, CA 90404
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessnewswire.com/newsroom/en/biotechnology/max-biopharma-and-revilico-announce-collaboration-on-target-identification-and-mechan-1057079

ACCESSWIRE
06 Aug 2025

https://www.prnewswire.com/news-releases/metaba-and-max-biopharma-announce-breakthrough-progress-on-next-generation-oxysterol-based-antibiotics-302379559.html

PR NEWSWIRE
20 Feb 2025

https://www.prnewswire.com/news-releases/max-biopharma-announces-key-update-on-its-anti-fibrotic-and-anti-inflammatory-oxysterol-drug-candidate-that-inhibits-mash-atherosclerosis-and-fat-tissue-inflammation-302285545.html

PR NEWSWIRE
24 Oct 2024

https://www.prnewswire.com/news-releases/avirmax-biopharma-inc-to-exhibit-development-of-next-generation-gene-therapies-for-ocular-diseases-at-the-aao-2024-annual-meeting-in-chicago-302277135.html

PR NEWSWIRE
15 Oct 2024

https://www.prnewswire.com/news-releases/max-biopharma-and-metaba-announce-collaboration-on-metabolomics-studies-302070283.html

PR NEWSWIRE
26 Feb 2024

https://www.prnewswire.com/news-releases/max-biopharma-announces-publication-of-proof-of-principle-regarding-its-oxysterol-lead-drug-candidate-oxy210-that-inhibits-fatty-liver-and-fibrosis-in-a-humanized-mouse-model-301374743.html

PRNEWSWIRE
13 Sep 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty